MeHow Innovative Ltd. A vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MeHow Innovative Ltd. A (301363.CS)

Q3 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

August 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Latest27 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.